FDA Approval Pitfalls, Surrogate Endpoints, and Postapproval Evidence Gaps: Scoping Review with ☸️SAIMSARA.

Name: SAIMSARA Evidence Object digital::FDA_APPROVAL_PITFALLS_SS
Creator: SAIMSARA
License: https://saimsara.com/license/

SAIMSARA

doi:10.62487/saimsarae25de34b

SAIMSARA Journal

Machine-Readable Science • ISSN 3054-3991

FDA Approval Pitfalls, Surrogate Endpoints, and Postapproval Evidence Gaps: Scoping Review with ☸️SAIMSARA.

Digital Health & Biotech

Issue 3, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsarae25de34b

Editorial note

• Last update: 2026-05-22 20:13:50

What is this paper about

FDA approval is not always the end of uncertainty — this evidence map shows how surrogate endpoints, accelerated pathways, thin pivotal trials, underrepresented populations, and delayed confirmatory evidence can leave major clinical questions unresolved after approval. The full evidence map helps clinicians, researchers, and policy-minded readers distinguish regulatory authorization from proven real-world benefit, safety, equity, and patient-centered value.

Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

Video summary generated from this ☸️SAIMSARA evidence map. Full reference-linked paper and evidence JSON are available after purchase.

Abstract: To identify and synthesize recurring pitfalls in FDA approval processes and postapproval implementation, emphasizing evidentiary uncertainty, surrogate endpoints, expedited pathways, trial design limitations, transparency gaps, population representativeness, safety monitoring, real-world effectiveness, and access after approval. The review uses 86 references and builds its evidence map from 69 original studies with 723986 total participants/sample observations (topic-deduplicated ΣN). Across diverse product classes and indications, the dominant signal is that FDA approval frequently occurs under residual evidentiary uncertainty rather than after definitive demonstration of patient-centered benefit, with recurrent reliance on surrogate endpoints, thin pivotal trial packages, and expedited pathways. This pattern is reinforced by underrepresentation of key demographic groups, incomplete transparency, and delayed or failed confirmatory trials, where only 43% of accelerated cancer approvals demonstrated clinical benefit in confirmatory studies. The findings suggest that clinicians, payers, and patients should interpret approval as a regulatory milestone rather than a guarantee of comparative effectiveness, equitable access, or real-world safety. Given the scoping nature of this synthesis and the heterogeneity of included evidence, future research should prioritize timely confirmatory randomized trials, indication-specific surrogate validation, and structured postapproval surveillance to close the gap between regulatory authorization and demonstrated patient benefit.

Keywords: FDA approval; Regulatory pitfalls; Accelerated approval; Surrogate endpoints; Clinical trial quality; Trial generalizability; Postmarketing surveillance; Safety reporting; Publication bias; Insurance coverage

Review Stats

Final search date and database lock: 2026-05-17 19:55:18 CEST
Plan: Pro (expanded craft tokens; source: Semantic Scholar)
Source: Semantic Scholar
Total Abstracts/Papers: 30786
Downloaded Abstracts/Papers: 1000
Included original and non-original Abstracts/Papers (all): 183
Included original Abstracts/Papers (Vote counting by direction of effect): 69
Reference Index (links used in paper): 86
Total participants/sample observations (topic deduplicated ΣN): 723986

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (86)

[1] Abstract 4370319: Early Safety Signals and Common Pitfalls of the TriClip™ System for Transcatheter Tricuspid Valve Repair: Analysis of FDA's MAUDE Database — https://doi.org/10.1161/circ.152.suppl_3.4370319
[2] The Morcellation "Debate" and the FDA 510(k) Process-A Call for Further Reform. — https://doi.org/10.1097/ogx.0000000000000733
[3] Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation — https://doi.org/10.1080/20008066.2024.2378651
[4] Reply by Authors. — https://doi.org/10.1097/ju.0000000000001132.02
[5] Editorial Comment. — https://doi.org/10.1097/ju.0000000000001132.01
[6] Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective — https://doi.org/10.1136/bmjonc-2024-000573
[7] FDA Approval Summary: Afamitresgene Autoleucel for Adults With HLA-Restricted MAGE-A4 Positive Unresectable or Metastatic Synovial Sarcoma After Prior Chemotherapy. — https://doi.org/10.1158/1078-0432.ccr-25-0595
[8] FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis — https://doi.org/10.1136/bmj-2022-073242

Unlock the full paper to view the complete Reference Index.